The US Food and Drug Administration (USFDA) has given its tentative approval for the company’s abbreviated new drug application (ANDA) for Amphetamine Extended-Release Orally Disintegrating Tablets in the 3.1mg, 6.3mg, 9.4mg, 12.5mg, 15.7mg and 18.8mg strengths. It is the generic equivalent of ADZENYS XR-ODT.
